Apolipoprotein E Genotype and Cognitive Performance in Breast Cancer Survivors
乳腺癌幸存者的载脂蛋白 E 基因型和认知表现
基本信息
- 批准号:7278630
- 负责人:
- 金额:$ 5.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-01 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdjuvant ChemotherapyAdverse effectsAftercareAllelesAlzheimer&aposs DiseaseApolipoprotein EAttentionBreastCancer PatientCancer SurvivorCardiovascular DiseasesCharacteristicsClassificationCognitionCognitiveCognitive deficitsComplexDementiaDiagnosisDisadvantagedEpisodic memoryExhibitsGeneticGenotypeImpaired cognitionLanguageLifeLinkMalignant NeoplasmsMeasurementMotorOutcomeParticipantPerformancePersonsPhysiologicalPublic HealthQuality of lifeRateRecording of previous eventsRelative (related person)ResearchReview LiteratureRiskRisk FactorsRoleSamplingSeveritiesSpeedStagingTestingTreatment-Related CancerUnited StatesWomancancer therapycardiovascular risk factorchemotherapycognitive controlcognitive functionexperiencegenetic risk factorhealthy agingindexinginterestmalignant breast neoplasmpsychologicsurvivorship
项目摘要
DESCRIPTION (provided by applicant): In recent years there has been considerable interest in the e4 allele of Apolipoprotein E (APOE), a genetic risk factor for Alzheimer's disease, as a risk factor for cognitive impairment in healthy aging. Recently, there has been growing recognition that women diagnosed with early stage breast cancer may experience cognitive problems as a consequence of adjuvant chemotherapy. In addition, research suggests that the presence of the e4 allele of APOE may also convey a disadvantage to the cognitive performance of breast cancer survivors. In the current proposal we examine cross-sectional differences and longitudinal changes in the cognitive functioning of a sample of breast cancer survivors and healthy controls as a function of APOE- e4 genotype. Specifically, we will assess APOE genotype of a group of breast cancer survivors who have been examined for over 3 years since the inception of treatment, as well as a matched sample of healthy controls who have been examined at a single measurement point. The specific aims are: 1) To compare cross-sectional differences in the cognitive performance of breast cancer survivors and healthy controls as a function of APOE-e4 genotype; 2) To examine longitudinal changes in cognitive performance among breast cancer survivors as a function of APOE-e4 genotype; and 3) To examine the role of cancer treatment-related and cardiovascular disease factors in the presence and severity of APOE-e4-related changes in cognitive performance among breast cancer survivors. Cognitive performance is indexed with multiple tests of episodic memory, attention, complex cognition, motor speed, and language. We predict that relative to healthy controls, the cognitive performance of breast cancer survivors will be poorer and breast cancer survivors who are APOE-e4 positive will perform most poorly. In terms of longitudinal changes, we predict that breast cancer survivors who are APOE-e4 positive will exhibit greater declines longitudinally, relative to non-e4 carriers. The results of the current proposal are relevant to attempts to describe factors that may predispose cancer survivors to negative cognitive outcomes after treatment. Identifying factors that may increase a person's risk of cognitive impairment following treatment for cancer is a great concern to public health. In the current proposal, we examine the potential of APOE-e4 genotype, known risk factor for Alzheimer's disease, to predispose breast cancer survivors for poor cognitive outcomes.
描述(由申请人提供):近年来,E4载脂蛋白E(APOE)的E4等位基因是阿尔茨海默氏病的遗传危险因素,这是健康衰老认知障碍的危险因素。最近,人们越来越认识到被诊断出患有早期乳腺癌的妇女可能由于辅助化疗而遭受认知问题。此外,研究表明,APOE的E4等位基因的存在也可能使乳腺癌幸存者的认知表现不利。在当前的建议中,我们检查了乳腺癌幸存者样本和健康对照样本的认知功能的横断面差异和纵向变化,这是APOE-E4基因型的函数。具体而言,我们将评估一组乳腺癌幸存者的APOE基因型,这些乳腺癌幸存者自治疗成立以来已经进行了3年的检查,以及在单个测量点进行了检查的匹配的健康对照样本。具体目的是:1)比较乳腺癌幸存者的认知性能和健康对照的横截面差异,这是APOE-E4基因型的函数; 2)检查乳腺癌幸存者在APOE-E4基因型的函数中认知表现的纵向变化; 3)检查乳腺癌幸存者认知性能变化的存在和严重程度,与癌症治疗相关和心血管疾病因素的作用。认知表现通过多个情节记忆,注意力,复杂的认知,运动速度和语言进行了多次索引。我们预测,相对于健康对照组,乳腺癌幸存者的认知表现较差,而APOE-E4阳性的乳腺癌幸存者的表现最差。就纵向变化而言,我们预测,相对于非E4载体,APOE-E4阳性的乳腺癌幸存者纵向下降。当前建议的结果与试图描述可能使癌症幸存者在治疗后产生负面认知结果的因素有关。确定可能增加一个人治疗癌症认知障碍风险的因素是公共卫生的极大关注。在当前的提案中,我们研究了APOE-E4基因型(已知的阿尔茨海默氏病风险因素)的潜力,使人们倾向于乳腺癌幸存者的认知结果不良。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRENT John SMALL其他文献
BRENT John SMALL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRENT John SMALL', 18)}}的其他基金
Daily Cognitive Functioning Among Cancer Survivors
癌症幸存者的日常认知功能
- 批准号:
9104114 - 财政年份:2015
- 资助金额:
$ 5.95万 - 项目类别:
Daily Cognitive Functioning Among Cancer Survivors
癌症幸存者的日常认知功能
- 批准号:
8958843 - 财政年份:2015
- 资助金额:
$ 5.95万 - 项目类别:
Apolipoprotein E Genotype and Cognitive Performance in Breast Cancer Survivors
乳腺癌幸存者的载脂蛋白 E 基因型和认知表现
- 批准号:
7114667 - 财政年份:2006
- 资助金额:
$ 5.95万 - 项目类别:
Lifestyle Activities and Changes in Cognitive Abilities
生活方式活动和认知能力的变化
- 批准号:
6951445 - 财政年份:2004
- 资助金额:
$ 5.95万 - 项目类别:
Lifestyle Activities and Changes in Cognitive Abilities
生活方式活动和认知能力的变化
- 批准号:
6806627 - 财政年份:2004
- 资助金额:
$ 5.95万 - 项目类别:
相似国自然基金
穿透性靶向胰腺癌内cDC1的纳米佐剂调控溶酶体逃逸促进放疗诱导ICD的机制研究
- 批准号:82303680
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
多级改造的工程化外泌体自佐剂疫苗平台实现鼻上皮细胞感染拟态和粘膜递送的研究
- 批准号:32371440
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
展示PD-L1抗体的纳米锰佐剂联合放疗以诱导原位肿瘤疫苗的产生及其机制的探究
- 批准号:32371518
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向FPPS的双磷酸疫苗佐剂的开发
- 批准号:82341040
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
应用于冠状病毒广谱疫苗开发的新型全链式免疫增强型佐剂研究
- 批准号:82341036
- 批准年份:2023
- 资助金额:110 万元
- 项目类别:专项基金项目
相似海外基金
3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
- 批准号:
10556192 - 财政年份:2023
- 资助金额:
$ 5.95万 - 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
- 批准号:
10315227 - 财政年份:2021
- 资助金额:
$ 5.95万 - 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
- 批准号:
443988 - 财政年份:2021
- 资助金额:
$ 5.95万 - 项目类别:
Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
- 批准号:
20K09011 - 财政年份:2020
- 资助金额:
$ 5.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
- 批准号:
19K09130 - 财政年份:2019
- 资助金额:
$ 5.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)